Loading company
Replimune Group, Inc.
REPL · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026
$12.55+1.5%Sep 28 close
- 1M
- -19.0%
- 6M
- +73.8%
- 1Y
- +189.2%
- 5Y
- -61.1%
REPL · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026
$12.55+1.5%Sep 28 close
Replimune Group, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$69.8M | -$86.7M | +19.53% |
| Profit per share | -$0.72 | -$0.95 | +24.21% |
| Free Cash Flow | -$75.7M | -$79.8M | +5.04% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Replimune Group, Inc. has no earnings call transcript available.
“The FDA’s approval of TUDRIQEV is a defining milestone for Replimune and, more importantly, for the patients facing advanced melanoma, where the need for safe and effective treatment options remains significant,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
RP1 (vusolimogene oderparepvec) is Replimune’s lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Replimune Group, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.